• Record: found
  • Abstract: found
  • Article: not found

Clinical profile of an atypical antipsychotic: risperidone.

Schizophrenia Bulletin

Antipsychotic Agents, Treatment Outcome, Schizophrenic Psychology, drug therapy, diagnosis, Schizophrenia, therapeutic use, adverse effects, Risperidone, Randomized Controlled Trials as Topic, Psychiatric Status Rating Scales, drug effects, Neurologic Examination, Humans, etiology, Dyskinesia, Drug-Induced

Read this article at

      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


      Stimulated by Dawkins and colleagues' (1999) and Remington and Kapur's (2000) calls to develop clinical profiles of the new atypical antipsychotic drugs and by Mattes's critiques (1997, 1998), we performed two sets of analyses for risperidone. First, we reanalyzed data from the North American risperidone trial: risperidone was superior to haloperidol to an equal degree in patients with and without the deficit syndrome, in patients with paranoid and nonparanoid schizophrenia, in treatment-resistant and treatment-responsive patients (patients hospitalized for longer and shorter periods), and in patients with or without weight gain. Moreover, risperidone was more effective than haloperidol on symptoms nonresponsive and responsive to haloperidol; its effects on negative symptoms were independent of its effects on extrapyramidal symptoms; and it was effective in treating depression in schizophrenia. Second, we performed a meta-analysis of 18 controlled risperidone trials: risperidone was consistently more effective than conventional antipsychotics in treating positive and negative symptoms.

      Related collections

      Author and article information



      Comment on this article